Abstracts tagged "drug therapy"

Abstract Number: 0489 • ACR Convergence 2021
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Kofi Mensah¹, Rajula Gaur¹, Jamie Connarn¹, Michael Thomas¹, Liangang Liu¹, Stuart Mair², Francisco Ramírez-Valle¹ and Maria Palmisano¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Quotient Sciences, Nottingham, United Kingdom
Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…
Abstract Number: 348 • 2019 ACR/ARP Annual Meeting
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Kenneth Saag¹, Andreas Reimold ², Lang Chen ¹, Huifeng Yun ¹ and Jeffrey Curtis ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²UT Southwestern Medical Center, Dallas
Background/Purpose: A variety of newer gout therapies have been introduced in recent years, some with potential safety concerns. However, uptake of these therapies and associated…
Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Rehan Azeem¹, Alan Kivitz ², Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…
Abstract Number: 1218 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients
Rehan Azeem¹, Justin Park ¹, Horacio Plotkin ¹, Alan Kivitz ², Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Long term gout treatment focuses on reducing sUA levels, thus allowing MSU crystals to dissolve. Rapid dissolution of MSU crystals during initial phase of…
Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Wesley DeHaan¹, Alan Kivitz ², Rehan Azeem ¹, Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Sheldon Leung ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…
Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle¹, Mary Adams ¹, Lisa Beebe ², Jian Chen ¹, Claudio Chuaqui ¹, Jamie Connarn ¹, Alan Corin ¹, Karen Dingley ¹, J. Michael Ellis ¹, Rajula Gaur ¹, Lawrence Hamann ¹, John Malona ¹, Kofi Mensah ¹ and Maria Palmisano ¹, ¹Celgene Corporation, Summit, NJ, ²Celgene Corporation, Cambridge, MA
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…
Abstract Number: 1952 • 2018 ACR/ARHP Annual Meeting
Experimental Tendinopathy Treatment with SM04755, a Topical Small Molecule Inhibitor of the Wnt Pathway
Vishal Deshmukh, Timothy Seo and Yusuf Yazici, Samumed, LLC, San Diego, CA
Background/Purpose: Tendinopathy is an inflammatory and degenerative disorder caused by injuries and overuse. The Wnt pathway is upregulated in chronic tendinopathy and involved in inflammation,…
Abstract Number: 2956 • 2018 ACR/ARHP Annual Meeting
Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
Meghna Jani, Belay Birlie Yimer, Therese Sheppard, Mark Lunt and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The opioid epidemic in the U.S. has led to similar concerns about prescribed opioids in the U.K. In new users, the rate of escalation…
Abstract Number: 2986 • 2018 ACR/ARHP Annual Meeting
The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
Nancy A. Shadick¹, Christine K Iannaccone², Patricia Katz³, Gabriela L. Maica⁴, Jonathan Coblyn⁵, Michael E Weinblatt⁶ and Jing Cui⁷, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³University of California San Francisco, San Francisco, CA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Modifiable lifestyle factors such as inactivity and obesity contribute to cognitive decline in the general population, but little is known about how these factors…
Abstract Number: 48 • 2018 ACR/ARHP Annual Meeting
In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis
Numa Simons¹, Andrey Kruglov², Yannick Degboe³, Arnaud Constantin³, Sergei Nedospasov⁴, Alain Cantagrel⁵, Jean-Luc Davignon⁶ and Benjamin Rauwel⁶, ¹Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁴4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation, ⁵Center of Rheumatology of CHU, Toulouse, France, ⁶CPTP, INSERM UMR 1043, Toulouse, France
In vivo demonstration of tmTNF reverse signaling: significance in the therapeutic response to anti-TNF agents during murine arthritis. N. Simons1,2, A. Kruglov 3, Y. Degboé 1,2, A.…
Abstract Number: 550 • 2018 ACR/ARHP Annual Meeting
Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
Michael Richter¹, Eric L. Matteson², John M. Davis III², Sara J. Achenbach³ and Cynthia S. Crowson³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Biologic discontinuation in rheumatoid arthritis: a population based study 1999-2017.Michael D Richter, Eric L Matteson, John M Davis III, Sara J Achenbach, Cynthia S Crowson…
Abstract Number: 525 • 2017 ACR/ARHP Annual Meeting
Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center
Richard Meehan¹, Isabelle Amigues², David Muram³, Eric Hoffman⁴, Jim Crooks⁵, Tho Truong⁶ and Pearlanne Zelarney⁷, ¹MEDICINE, National Jewish Health, Denver, CO, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Medicine/Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Rheumatology, National Jewish Health, Denver, CO, ⁷Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: The goal of therapy of rheumatoid arthritis (RA) is to achieve a state of low disease activity (LDA) or remission and reduce joint damage…
Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis
Tomokazu Nagakura¹, Takuma Ito², Masateru Kusuda², Tuyoshi Yamatou², Tomohiro Kubota², Yuuichi Yamasaki², Yukiko Nonaka², Tomoko Takezaki², Harumi Akaike³, Yasuhito Nerome², Hiroyuki Imanaka² and Syuji Takei⁴, ¹Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, ²Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ³Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, ⁴Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan
Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Gercek Can¹, Ediz Dalkılıc², Yavuz Pehlivan², Soner Senel³, Servet Akar⁴, Dilek Solmaz⁵, Suleyman Serdar Koca⁶, Nevsun İnanc⁷, Pamir Atagunduz⁷, Ayten Yazıcı⁸, Ayse Cefle⁸, Berna Goker⁹, Berrin Zengin¹, Sadettin Uslu¹⁰, Nurullah Akkoc¹¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Rheumatology, Uludag University Faculty of Medicine Rheumatology, bursa, Turkey, ³Rheumatology, Erciyes University Faculty of Medicine Rheumatology, kayseri, Turkey, ⁴Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, izmir, Turkey, ⁶Rheumatology, Fırat University Faculty of Medicine, elazıg, Turkey, ⁷Rheumatology, Marmara University Faculty of Medicine Rheumatology, istanbul, Turkey, ⁸Rheumatology, Kocaeli University Faculty of Medicine Rheumatology, kocaeli, Turkey, ⁹Rheumatology, Gazi Universty of Fakulty of Medicine, ankara, Turkey, ¹⁰Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ¹¹Rheumatology, Private Practice, Rheumatology, İzmir, Turkey
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…
Abstract Number: 1547 • 2017 ACR/ARHP Annual Meeting
Dose Tapering of TNFi in Patients with Axial Spondyloarthritis: An Observational Cohort Study from Nationwide Korean College of Rheumatology Biologic Registry (KOBIO)
Jun Won Park¹, Jin Kyun Park¹, Kichul Shin², Yong-Beom Park³, Eun Bong Lee¹, Yeong Wook Song⁴ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Yonsei University Severance Hospital, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: To compare the clinical efficacy of dose-tapering strategy of tumor-necrosis factor inhibitor (TNFi) with that of standard-dose TNFi treatment in patients with spondyloarthritis (SpA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].